TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02532660
Drug: Escitalopram 10mg
Normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10mg (1 pill once a day)
Study: NCT02221180
Drug: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
Study: NCT02221180
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
Study: NCT02221180
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
Study: NCT00067782
Drug: Atazanavir (Week 24 switch)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 400mg, Once daily, 48 weeks.
Study: NCT02532660
Drug: Escitalopram Placebo
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram Placebo (1 pill once a day)
Study: NCT01276457
Drug: Everolimus 0.25 and 0.75 mg tablets
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
Study: NCT01276457
Drug: Cyclosporine very low dose (150-300 ng/mL) microemulsion
Normalized name: cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
Study: NCT01276457
Drug: Cyclosporine low dose (350-500 ng/mL) microemulsion
Normalized name: cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
Study: NCT00093821
Drug: tanespimycin
Normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00498355
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
Study: NCT01555125
Drug: secukinumab 150 mg
Normalized name: secukinumab 150 MG/ML
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
Study: NCT01555125
Drug: secukinumab 300 mg
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
Study: NCT01204255
Drug: lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given topically
Study: NCT01204255
Drug: diphenhydramine hydrochloride
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given topically
Study: NCT01204255
Drug: haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given topically
Study: NCT03953261
Drug: Curcumin supplement
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention is 2 grams of curcumin supplement per day
Study: NCT02011126
Drug: Imetelstat Sodium
Normalized name: imetelstat sodium
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04644354
Drug: Nifedipine 10 mg
Normalized name: nifedipine 10 MG
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
Study: NCT01404572
Drug: Atazanavir (current formulation)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
Study: NCT01404572
Drug: Atazanavir, powder for oral use 1 (POU1)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
Study: NCT01404572
Drug: Atazanavir (POU2)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
Study: NCT02940990
Drug: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two-drug regimen
Study: NCT03867734
Drug: Aztreonam
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2g IM Aztreonam
Study: NCT03609827
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02265237
Drug: ombitasvir/paritaprevir/ritonavir
Normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablets
Study: NCT02265237
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablets
Study: NCT00650546
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mcg twice a day titrated to 10 mcg twice a day
Study: NCT03627403
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly.
Study: NCT02450994
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01344460
Drug: Gadobutrol (Gadovist, BAY86-4875)
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single bolus injection of approx. 0.1mmol/kg
Study: NCT04917679
Drug: Eltrombopag plus diacerein
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10\^9/L as follows: (1) if platelet count is less than 150 × 10\^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10\^9/L to 250 × 10\^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10\^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10\^9/L.
Study: NCT04917679
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10\^9/L to 150 × 10\^9/L.
Study: NCT04128579
Drug: Itolizumab [Bmab 600]
DrugBank: Itolizumab (DB16207)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQ001
Study: NCT03060603
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
Study: NCT00507793
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00507793
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00113438
Drug: Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
Study: NCT00006060
Drug: standard gadolinium contrast
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00883480
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/day 1 x 4 cycles
Study: NCT02386566
Drug: natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: As described in the treatment arm
Study: NCT03387852
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study: NCT03387852
Drug: Fluticasone or Fluticasone/salmeterol combination
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
Study: NCT03387852
Drug: Placebo for dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study: NCT00883480
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
Study: NCT00883480
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles
Study: NCT00883480
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day x 21 days
Study: NCT00840944
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: somatropin 0.050 mg/kg/day
Study: NCT00840944
Drug: triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triptorelin 3.75 mg each month
Study: NCT02133846
Drug: TPI-287 20 mg/m2
DrugBank: TPI-287 (DB17168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
Study: NCT02133846
Drug: TPI-287 6.3 mg/m2
DrugBank: TPI-287 (DB17168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
Study: NCT00098124
Drug: milnacipran hydrochloride
Normalized name: Milnacipran Hydrochloride
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02269293
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02269293
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02269293
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02121847
Drug: cyclosporine 0.05% ophthalmic emulsion
Normalized name: Cyclosporine 0.05% Ophthalmic Emulsion
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
Study: NCT02121847
Drug: carboxymethylcellulose-based lubricant eye drops
Normalized name: carboxymethylcellulose Ophthalmic Solution [Eyes Alive Lubricating]
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
Study: NCT01255046
Drug: Donepezil,
Normalized name: donepezil, memantine and Ginkgo folium
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/tab, 1 tab/day for 72 weeks
Study: NCT01255046
Drug: STA-1
Normalized name: 17β-hydroxyandrosta-1,4-dien-3-one
DrugBank: 3,4-dihydroxy-9,10-secoandrosta-1(10),2,4-triene-9,17-dione (DB08542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg/tab, 2 tab/tid for 72 weeks
Study: NCT01028573
Drug: Miralax mixed with Gatorade
Normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
Study: NCT01028573
Drug: Miralax
Normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
Study: NCT00325793
Drug: Nicardipine
Normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00609739
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients \>40 kg with normal renal function (creatinine \<1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
Study: NCT00609739
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3000 mg/m\^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m\^2/day) on days -9 through -4.
Study: NCT00066625
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00066625
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06484439
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg PO PRN
Study: NCT00383422
Drug: Arzoxifene
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg, oral, tablet, once a day for 52 weeks
Study: NCT00383422
Drug: Raloxifene
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg, oral, tablet, once a day for 52 weeks
Study: NCT00609739
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with absolute neutrophil count (ANC) \<0.2 x 10\^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10\^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
Study: NCT00609739
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
Study: NCT00609739
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m\^2 over 30 minutes intravenously (IV) on days -9 through -7.
Study: NCT02643186
Drug: preoperative vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
Study: NCT02238496
Drug: Perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
Study: NCT02238496
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
Study: NCT01114958
Drug: Cisplatin, Thiosulfate
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (150 mg/m\^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m\^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m\^2).
Study: NCT00621855
Drug: dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules, twice daily, 26 weeks treatment
Study: NCT03787940
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
Study: NCT03359980
Drug: fecal microbiota transfer
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: transfer of fecal microbiota from healthy donors to the patients
Study: NCT00748046
Drug: Radium-223 chloride (BAY88-8223)
Normalized name: Radium-223 chloride
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
Study: NCT04482751
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: AMH will be measured during ovarian stimulation with corifollitropin alfa
Study: NCT02352948
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
Study: NCT02352948
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
Study: NCT02352948
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
Study: NCT02352948
Drug: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
Study: NCT02352948
Drug: tremelimumab (anti-CTLA4)
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tremelimumab (anti-CTLA4) treatment by intravenous infusion
Study: NCT04402177
Drug: Methyl Prednisolonate
Normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid treatment
Study: NCT00354874
Drug: salmeterol 50mcg
Normalized name: FLUTICAS 500/SALMETEROL 50MCG INHL DISK
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: salmeterol
Study: NCT00848679
Drug: Epidural lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
Study: NCT00848679
Drug: Epidural lidocaine 2%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
Study: NCT03413436
Drug: Lobaplatin
Normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: at least one cycle adjuvant chemotherapy after esophagectomy
Study: NCT03413436
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at least one cycle adjuvant chemotherapy after esophagectomy
Study: NCT02289300
Drug: DCB-BO1202
Normalized name: DCB
DrugBank: Dichlorobenzene (DB14046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) \* 8 cycles)